CMS: anti-amyloid drug Leqembi (lecanemab) does not meet the “affordable and obligatory” customary required for wider Medicare protection
CMS Sticks to Sharply Limited Coverage of New Alzheimer’s Drug, Leqembi (Managed Well beingcare Govt): For now, CMS (Observe: Centers...
